Patients Medical Professionals Careers Investors Therapy Sites Global Sites About Us Research & Pipeline Therapies Global Impact Newsroom About Us Research & Pipeline Therapies Global Impact Newsroom Therapies We develop therapies for serious medical conditions with few or no treatment options. Filter by: All Multiple Sclerosis Spinal Muscular Atrophy Biosimilars Spinal Muscular Atrophy SPINAL MUSCULAR ATROPHY We are proud to bring the first treatment to the SMA community who inspire us every day. Biogen is deeply committed to helping improve the lives of people with SMA and we work closely with the SMA patient community with the goal of understanding and incorporating the perspectives of patients and families into the decisions we make. This new treatment is now approved by the United States' Food and Drug Administration and the European Union’s European Medicines Agency. SPINRAZA® availability in the EU will vary by country, per local reimbursement and access pathways. The SMA360 patient assistance program is not applicable in Europe. SMA Support Resources (for U.S. only) For further information on the expanded access progam (EAP) for nusinersen in your country, please or contact . SEE MORE About Us About Biogen A Leader In Multiple Sclerosis Executive Leadership Board of Directors History Manufacturing Biosimilars Positions & Policy Perspectives Contact Us Governance Research & Pipeline Pipeline Clinical Trials Access to Investigational Therapies BiogenScience Areas of Research Postdoc Program Collaborations Medical Research portal Therapies Multiple Sclerosis AVONEX® FAMPYRA® PLEGRIDY® TECFIDERA® TYSABRI® ZINBRYTA® Spinal Muscular Atrophy SPINRAZA® Biosimilars BENEPALI® FLIXABI® IMRALDI® Partnered GAZYVA® RITUXAN® Global Impact Science that matters Biogen Foundation Community Lab Supplier Diversity Grants Office Patients Medical Professionals Careers Investors Follow us on: Twitter LinkedIn Facebook YouTube Privacy Policy Terms & Conditions Sitemap Forward-Looking Statements Community Guidelines Contact Us © 2017 Biogen